Published online Aug 28, 2009. doi: 10.3748/wjg.15.4044
Revised: July 21, 2009
Accepted: July 28, 2009
Published online: August 28, 2009
AIM: To evaluate the safety and long-term prognosis of conservative resection (CR) for benign or borderline tumor of the proximal pancreas.
METHODS: We retrospectively analyzed 20 patients who underwent CR at the Second Affiliated Hospital of Zhejiang University School of Medicine between April 2000 and October 2008. For pancreaticojejunostomy, a modified invagination method, continuous circular invaginated pancreaticojejunostomy (CCI-PJ) was used. Modified continuous closed lavage (MCCL) was performed for patients with pancreatic fistula.
RESULTS: The indications were: serous cystadenomas in eight patients, insulinomas in six, non-functional islet cell tumors in three and solid pseudopapillary tumors in three. Perioperative mortality was zero and morbidity was 25%. Overall, pancreatic fistula was present in 25% of patients. At a mean follow up of 42.7 mo, all patients were alive with no recurrence and no new-onset diabetes mellitus or exocrine dysfunction.
CONCLUSION: CR is a safe and effective procedure for patients with benign tumors in the proximal pancreas, with careful CCI-PJ and postoperative MCCL.
- Citation: Huang H, Dong X, Gao SL, Wu YL. Conservative resection for benign tumors of the proximal pancreas. World J Gastroenterol 2009; 15(32): 4044-4048
- URL: https://www.wjgnet.com/1007-9327/full/v15/i32/4044.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.4044
Pancreaticoduodenectomy (PD) and distal pancreatectomy (DP) are standard operations for tumors located in the proximal portion of the pancreas. However, these standard techniques are associated with a significant risk of long-term endocrine and exocrine impairment. Recently, there has been increased interest in conservative surgery in an attempt to preserve as much as possible the pancreatic parenchyma and integrated upper digestive system anatomy. For patients with benign or low-grade malignant tumors, conservative resection (CR) such as central pancreatectomy or enucleation has been investigated to maintain the normal upper digestive system anatomy, and to reduce the risk of development of exocrine and endocrine functional insufficiency. Although CR of the proximal pancreas may be more appropriate and less time-consuming, it has not been used widely previously because of its high morbidity, especially pancreatic fistula. The focus of this study was to evaluate the safety and outcomes of CR for benign or borderline tumors of the head, neck and proximal part of the pancreas.
Twenty patients with benign or borderline tumors localized in the head, neck and proximal part of the pancreas, who were treated with central pancreatectomy (n = 11) and enucleation (n = 9), between April 2000 and October 2008, were analyzed retrospectively. Data on preoperative, intraoperative and postoperative care were collected and maintained on a secure database. Preoperative parameters included demographics, clinical presentation, and exocrine and endocrine evaluation. Preoperative imaging modalities such as abdominal spiral contrast CT and ultrasound imaging were used to evaluate the suitability for surgical resection in all cases. Intraoperative details including operative time, total blood loss, transfusion and the method of surgery were recorded. Postoperative events and clinical outcomes such as surgical complications, mortality, pathological data and long-term follow-up were recorded carefully.
Postoperative pancreatic fistula was defined as drainage of > 50 mL per 24 h of fluid, with amylase content > 3 times serum amylase activity for > 10 d after operation[12]. Perioperative mortality was defined as death in the hospital or within 30 d. Delayed gastric emptying (DGE) was defined to be present when nasogastric intubation was maintained for ≥ 10 d, combined with at least one of the following: vomiting after removal of the nasogastric tube, reinsertion of nasogastric tube, or failure to restore oral feeding[3]. Fasting glucose blood level was used for the diagnosis of new-onset diabetes[4]. Exocrine insufficiency was defined as steatorrhea and weight loss requiring pancreatic enzymes supplementation.
CR was indicated for benign or low-grade malignant lesions localized in the proximal pancreas, especially in young patients. Simple enucleation was used when the tumor was near or at the surface of the pancreas. Great care had to be taken to avoid the main pancreatic duct injury and obtain complete excision during surgery, otherwise central pancreatectomy was chosen. Central pancreatectomy was indicated when the tumor was deeply embedded in the pancreatic parenchyma without clear margin, and was not suitable for enucleation. The distal remnant of the pancreas was kept at least 5 cm in length.
Central pancreatectomy was performed as reported previously[5–7]. After transecting the pancreas by electrocautery to the left and right of the tumor, the main pancreatic duct was ligated using a 3-0 silk suture, and the proximal pancreatic stump was oversewn with 3-0 polypropylene in a continuous running fashion. Reconstruction of the distal pancreatic remnant was accomplished with a retrocolic Roux-en-Y pancreaticojejunostomy. For pancreaticojejunostomy, a modified invagination method, continuous circular invaginated pancreaticojejunostomy (CCI-PJ), was used. The remnant of the pancreas was dissected for about 1-3 cm from the cut edge, and several small veins running between the pancreas and the splenic vein had to be divided and ligated. The pancreatic stump was invaginated into the jejunum, and a single-layer continuous circular anastomosis with 3-0 polypropylene was performed between the full thickness of the resected jejunum and the body of the pancreas. The largest silicon stent that could be passed into the main pancreatic duct was used in all these patients. Finally, four 24-F drainage catheters were placed near the pancreatic anastomosis.
Antibiotics were used prophylactically for 5 d after operation, but octreotide was not used routinely. Parenteral nutrition and early enteral feeding were administered. Enteral feeding usually began gradually on postoperative day 3. The fluid from the drain tube placed near the pancreatic anastomosis was monitored routinely for volume and amylase level. For those patients with pancreatic fistulas, modified continuous closed lavage (MCCL) was performed as reported in our previous study[8]. A long 6/8-F silicon tube was inserted into each of the 24-F drainage catheters and pulled out from the lateral part of the catheter about 3-5 cm to the external end. The drainage catheter was connected with a drainage pack. A high volume (20-50 L/d) of normal saline was infused through the silicon tube and eventually ran out into the drainage pack through the same rubber catheter. The lavage volume and duration was adjusted according to the appearance and quality of the outflowing liquid.
Results are presented as mean ± SD. Statistical analysis was performed using SPSS version 15.0 statistical software. Student’s t test was used for comparison of two independent samples. Categorical variables were compared using the χ2 or Fisher exact test. P < 0.05 was considered statistically significant.
The characteristics of CR patients are summarized in Table 1. Eight patients had serous cystadenoma, six had insulinoma, three had solid pseudopapillary tumors, and three had non-functional islet cell tumors. Each tumor was resected with clear margins, as determined by intraoperative frozen section and confirmed by final pathological examination. Mean tumor diameter was 2.9 cm (range 0.8-10.0 cm). Mean operating time was 236.5 min (range 75-405 min). The mean intraoperative blood loss was 350 mL (range 100-1200 mL). Three patients (15%) required intraoperative blood transfusion. The mortality was zero and morbidity was 25%. Overall occurrence of pancreatic fistula was 25% and DGE was 20%. Compared with 12 cases of PD for benign tumors in the proximal pancreas during the same period in our hospital, the characteristics did not differ significantly between the two groups. The mortality was zero and the morbidity was 25% in both groups.
Patient No. | Age (yr) | Sex | Pathological description | Size (cm) | Lesion location | Operation | Complication | Follow up (mo) |
1 | 75 | F | Serous cystadenoma | 2.0 | Neck | Central pancreatectomy | Pancreatic fistula (significant case) Hemorrhage DGE | 100 |
2 | 66 | M | Non-functional islet cell tumor | 2.6 | Neck | Enucleation | No | 89 |
3 | 38 | F | Insulinoma | 1.0 | Proximal body | Enucleation | No | 76 |
4 | 39 | M | Insulinoma | 0.8 | Uncinate process | Enucleation | No | 75 |
5 | 62 | M | Non-functional islet cell tumor | 2.5 | Proximal body | Central pancreatectomy | Pancreatic fistula (significant case), perianastomotic fluid collection with infection, DGE | 62 |
6 | 45 | F | Serous cystadenoma | 2.8 | Proximal body | Central pancreatectomy | No | 54 |
7 | 12 | F | Solid pseudopapillary tumor | 3.0 | Neck | Enucleation | No | 46 |
8 | 28 | F | Solid pseudopapillary tumor | 10.0 | Head | Enucleation | Pancreatic fistula (the largest daily volume > 1000 mL in the early postoperative period) | 46 |
9 | 40 | F | Insulinoma | 2.0 | Proximal body | Central pancreatectomy | No | 45 |
10 | 61 | F | Solid pseudopapillary tumor | 1.8 | Neck | Central pancreatectomy | No | 45 |
11 | 39 | M | Insulinoma | 1.7 | Proximal body | Enucleation | No | 43 |
12 | 62 | F | Non-functional islet cell tumor | 2.0 | Neck | Central pancreatectomy | No | 34 |
13 | 47 | F | Serous cystadenoma | 3.0 | Neck | Central pancreatectomy | No | 34 |
14 | 29 | F | Insulinoma | 2.0 | Neck | Central pancreatectomy | No | 24 |
15 | 29 | M | Insulinoma | 1.5 | Head | Enucleation | No | 23 |
16 | 55 | F | Serous cystadenoma | 2.0 | Neck | Central pancreatectomy | Pancreatic fistula, DGE | 21 |
17 | 32 | M | Serous cystadenoma | 4.0 | Proximal body | Central pancreatectomy | No | 13 |
18 | 39 | F | Serous cystadenoma | 5.0 | Neck | Enucleation | Pancreatic fistula, DGE | 10 |
19 | 66 | M | Serous cystadenoma | 4.0 | Proximal body | Central pancreatectomy | No | 7 |
20 | 42 | M | Serous cystadenoma | 5.0 | Head | Enucleation | No | 6 |
It should be pointed out that, among five cases of fistula from 20 CR operations, there were two from nine enucleations and three from 11 central pancreatectomies. Fistula after enucleation usually healed within 7-15 d, by multiple drainage without special intervention. However, in one case of enucleation for a 10-cm solid pseudopapillary tumor located at the head of the pancreas, a small rupture in the main pancreatic duct was found during surgery, and it was repaired by primary suturing with 5-0 polypropylene. The volume of drainage came up to > 1 L/d at the early stage after operation. With MCCL, the fistula healed 15 d later. In the three fistulas from 11 central pancreatectomies, two cases presented with clinically significant pancreatic fistulas that required further medical intervention (Table 1).
After a postoperative follow up of 42.7 mo (range 6-100 mo), all patients were alive without tumor recurrence. No patients developed new-onset diabetes mellitus. However, two cases of new-onset diabetes developed in the PD group. None experienced clinical exocrine insufficiency or required pancreatic enzyme supplements, and three patients needed exocrine substitution in the PD group. Exocrine function of the pancreas was better preserved in the CR than PD group (P < 0.05).
For tumors located in the head, neck and proximal pancreas, standard or extended pancreatectomy, such as PD, DP and extended DP, which involves resection of a notable amount of normal parenchyma, has been indicated for benign lesions. It has been reported that the rates of new-onset diabetes mellitus and exocrine insufficiency after PD were 10%-40% and 22%-60% respectively[79–12]. Previous reports have shown that 72% of patients became insulin dependent after subtotal left pancreatectomy, whereas 85%-95% resection caused diabetes in all patients[1314]. Besides pancreatic parenchyma, the integrated upper digestive and biliary anatomy also plays a key role in maintaining consequent digestive, immunological and coagulative function and neurohormonal regulation of insulin activity[15]. In addition, Reid-Lombardo et al[16] have reported that the 5- and 10-year cumulative probability of biliary stricture after PD for benign lesions was 8% and 13%; that is why, in recent years, CR, such as central pancreatectomy and enucleation, has been investigated with great interest. In the present study, with a mean of 42.7 mo follow-up, there was no new-onset diabetes mellitus and pancreatic exocrine insufficiency, which is the same as previously reported[17–23]. Moreover, in our study, the mean age of patients was only 45.3 years old. For these young patients with benign pancreatic disease, CR might be much more significant in achieving good quality of life, because CR can avoid long-term anastomotic complications and pancreatic insufficiency.
However, conservative pancreatectomy has not been used widely to date because of its high morbidity rate, especially pancreatic fistula. It has been reported that the morbidity rate of CR ranged from 35% to 63% (Table 2), which is much higher than that for PD and DP[6722–25]. In our study, the morbidity rate of CR was 25%. Overall pancreatic fistula rate was 25%, and DGE rate was 20%.
Author | Year | No. of cases | Morbidity rate (%) | Pancreatic fistula (%) | Mortality rate (%) |
Sperti et al[21] | 2000 | 101 | 40 | 30 | 0 |
Balzano et al[6] | 2003 | 462 | 51 | 39 | 0 |
Efron et al[24] | 2004 | 141 | 50 | 36 | 0 |
Roggin et al[23] | 2006 | 101 | 60 | 30 | 0 |
Brown et al[25] | 2006 | 101 | 60 | 40 | 0 |
Christein et al[22] | 2006 | 81 | 63 | 63 | 0 |
Falconi et al[7] | 2007 | 363 | 44 | 31 | 0 |
Present series | 2007 | 20 | 25 | 25 | 0 |
The pancreatic fistula rate in our study was a little better than that reported since 2000 (Table 2), which has ranged from 30% to 63%[6722–25]. In our study, although fistula developed in five of 20 patients, only two with clinically significant fistula required further intervention. According to our experience here, CCI-PJ and efficient MCCL might be responsible for lower morbidity in CR. With CCI-PJ, the stump of the pancreas and the cut edge of the jejunum could be connected closely with polypropylene sutures, which were used for anastomosis of the blood vessels. After postoperative pancreatic fistula has been diagnosed clinically, postoperative MCCL with a high volume of normal saline (20-50 L/d) was necessary to control the pancreatic fistula effectively. The advantage of MCCL compared with general lavage is that there was no concern about the imbalance between ingoing and outgoing fluids because the small silicon tube for irrigation was placed at the tip of the large catheters for outgoing fluid. With MCCL, most patients with pancreatic fistula recover without further surgical intervention.
In conclusion, CR for benign or borderline tumors of the proximal pancreas could be performed safely with careful CCI-PJ and postoperative MCCL. It is useful for preserving long-term pancreatic function.
In recent years, there has been a marked increase of incidentally discovered benign or borderline tumor of the pancreas using advanced diagnostic imaging techniques. The resection of benign lesions located in the proximal portion of the pancreas traditionally has been accomplished by pancreaticoduodenectomy and distal pancreatectomy. These extended resections result in removal of normal pancreatic tissue, which increased the risk of loss of exocrine and endocrine function.
Conservative pancreatic resection including pancreatic enucleation and central pancreatectomy has evolved as a means of preserving as much as possible the pancreatic parenchyma and integrated upper digestive system anatomy. In the present study, the authors evaluated the safety and long-term prognosis of patients who underwent conservative resection (CR) for benign or borderline tumors of the proximal pancreas.
CR for benign or borderline tumors of the proximal pancreas could be performed safely with careful continuous circular invaginated pancreaticojejunostomy and postoperative modified continuous closed lavage (MCCL). It is effective for preserving long-term pancreatic function.
CR is a safe and reasonable technique for benign tumors or lesions of low malignant potential in the proximal pancreas. To obtain good results, careful patient selection and experience in pancreatic surgery are of paramount importance in this setting.
Central pancreatectomy, also known as middle pancreatectomy, is a segmental resection of the pancreas. Dagradi and Serio performed the first central pancreatectomy with an oncological indication in 1984. The main advantage of this operation is that it permits preservation of most of the pancreatic parenchyma, extrahepatic bile duct, duodenum, and spleen.
The article is well written and demonstrates the results of CR of benign tumor of the proximal pancreas. CR is a procedure that offers benefits for benign and low-grade malignant pancreatic tumors, because it allows preservation of endocrine and exocrine functions. A lower risk of typical postoperative complications following pancreatectomy is especially important in young patients, which is stressed by authors of this study. A presented method (MCCL) of management in patients with pancreatic fistula may be useful for other researchers.
1. | Büchler MW, Friess H, Wagner M, Kulli C, Wagener V, Z'Graggen K. Pancreatic fistula after pancreatic head resection. Br J Surg. 2000;87:883-889. [Cited in This Article: ] |
2. | Yeo CJ, Cameron JL, Maher MM, Sauter PK, Zahurak ML, Talamini MA, Lillemoe KD, Pitt HA. A prospective randomized trial of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy. Ann Surg. 1995;222:580-588; discussion 588-592. [Cited in This Article: ] |
3. | Yeo CJ, Barry MK, Sauter PK, Sostre S, Lillemoe KD, Pitt HA, Cameron JL. Erythromycin accelerates gastric emptying after pancreaticoduodenectomy. A prospective, randomized, placebo-controlled trial. Ann Surg. 1993;218:229-237; discussion 237-238. [Cited in This Article: ] |
4. | Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539-553. [Cited in This Article: ] |
5. | Crippa S, Bassi C, Salvia R, Falconi M, Butturini G, Pederzoli P. Enucleation of pancreatic neoplasms. Br J Surg. 2007;94:1254-1259. [Cited in This Article: ] |
6. | Balzano G, Zerbi A, Veronesi P, Cristallo M, Di Carlo V. Surgical treatment of benign and borderline neoplasms of the pancreatic body. Dig Surg. 2003;20:506-510. [Cited in This Article: ] |
7. | Falconi M, Mantovani W, Crippa S, Mascetta G, Salvia R, Pederzoli P. Pancreatic insufficiency after different resections for benign tumours. Br J Surg. 2008;95:85-91. [Cited in This Article: ] |
8. | Dong X, Gao SL, Xie QP, Xu L, Xu YL, Wu YL. In situ high-volume modified continuous closed and/or open lavage for infected necrotizing pancreatitis. Pancreas. 2008;36:44-49. [Cited in This Article: ] |
9. | Andersen HB, Baden H, Brahe NE, Burcharth F. Pancreaticoduodenectomy for periampullary adenocarcinoma. J Am Coll Surg. 1994;179:545-552. [Cited in This Article: ] |
10. | Lemaire E, O'Toole D, Sauvanet A, Hammel P, Belghiti J, Ruszniewski P. Functional and morphological changes in the pancreatic remnant following pancreaticoduodenectomy with pancreaticogastric anastomosis. Br J Surg. 2000;87:434-438. [Cited in This Article: ] |
11. | Huang JJ, Yeo CJ, Sohn TA, Lillemoe KD, Sauter PK, Coleman J, Hruban RH, Cameron JL. Quality of life and outcomes after pancreaticoduodenectomy. Ann Surg. 2000;231:890-898. [Cited in This Article: ] |
12. | McLeod RS, Taylor BR, O'Connor BI, Greenberg GR, Jeejeebhoy KN, Royall D, Langer B. Quality of life, nutritional status, and gastrointestinal hormone profile following the Whipple procedure. Am J Surg. 1995;169:179-185. [Cited in This Article: ] |
13. | Frey CF, Child CG, Fry W. Pancreatectomy for chronic pancreatitis. Ann Surg. 1976;184:403-413. [Cited in This Article: ] |
14. | Morrow CE, Cohen JI, Sutherland DE, Najarian JS. Chronic pancreatitis: long-term surgical results of pancreatic duct drainage, pancreatic resection, and near-total pancreatectomy and islet autotransplantation. Surgery. 1984;96:608-616. [Cited in This Article: ] |
15. | Yasuda H, Takada T, Toyota N, Amano H, Yoshida M, Takada Y, Takada K, Hijikata H. Limited pancreatectomy: significance of postoperative maintenance of pancreatic exocrine function. J Hepatobiliary Pancreat Surg. 2000;7:466-472. [Cited in This Article: ] |
16. | Reid-Lombardo KM, Ramos-De la Medina A, Thomsen K, Harmsen WS, Farnell MB. Long-term anastomotic complications after pancreaticoduodenectomy for benign diseases. J Gastrointest Surg. 2007;11:1704-1711. [Cited in This Article: ] |
17. | Warshaw AL, Rattner DW, Fernández-del Castillo C, Z'graggen K. Middle segment pancreatectomy: a novel technique for conserving pancreatic tissue. Arch Surg. 1998;133:327-331. [Cited in This Article: ] |
18. | Iacono C, Bortolasi L, Serio G. Is there a place for central pancreatectomy in pancreatic surgery? J Gastrointest Surg. 1998;2:509-516; discussion 516-517. [Cited in This Article: ] |
19. | Rotman N, Sastre B, Fagniez PL. Medial pancreatectomy for tumors of the neck of the pancreas. Surgery. 1993;113:532-535. [Cited in This Article: ] |
20. | Sauvanet A, Partensky C, Sastre B, Gigot JF, Fagniez PL, Tuech JJ, Millat B, Berdah S, Dousset B, Jaeck D. Medial pancreatectomy: a multi-institutional retrospective study of 53 patients by the French Pancreas Club. Surgery. 2002;132:836-843. [Cited in This Article: ] |
21. | Sperti C, Pasquali C, Ferronato A, Pedrazzoli S. Median pancreatectomy for tumors of the neck and body of the pancreas. J Am Coll Surg. 2000;190:711-716. [Cited in This Article: ] |
22. | Christein JD, Smoot RL, Farnell MB. Central pancreatectomy: a technique for the resection of pancreatic neck lesions. Arch Surg. 2006;141:293-299. [Cited in This Article: ] |
23. | Roggin KK, Rudloff U, Blumgart LH, Brennan MF. Central pancreatectomy revisited. J Gastrointest Surg. 2006;10:804-812. [Cited in This Article: ] |
24. | Efron DT, Lillemoe KD, Cameron JL, Yeo CJ. Central pancreatectomy with pancreaticogastrostomy for benign pancreatic pathology. J Gastrointest Surg. 2004;8:532-538. [Cited in This Article: ] |
25. | Brown KM, Shoup M, Abodeely A, Hodul P, Brems JJ, Aranha GV. Central pancreatectomy for benign pancreatic lesions. HPB (Oxford). 2006;8:142-147. [Cited in This Article: ] |